GGrantIndex
← Leaderboards

Danuta Szczesna-Cordary

University Of Miami School Of Medicine

$10,536,169
Attributed
$11,340,467
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200523
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$11,340,467 · 9

By mechanism

R01$10,554,082 · 6
R56$487,511 · 1
T32$289,022 · 1
P41$9,852 · 1

Top collaborators

Most similar at University Of Miami School Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Myocardium

Research focus

MyocardiumMuscle ContractionMyosin AtpasePhenotypeCardiacSkinMolecularMutationMuscle FibersMuscleHeartTransgenic OrganismsMutantBaseLinkPapillary MuscleCardiac Muscle ContractionTransgenic MiceActinsRegulationIn VivoSarcomeresGenesLight

Grant awards (29)

Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle$383,750
R01 · FY2023 · HL · contact PI
Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle$383,750
R01 · FY2022 · HL · contact PI
Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle$383,750
R01 · FY2021 · HL · contact PI
Redefining The Role Of Myosin Essential Light Chain In Cardiac Muscle$383,750
R01 · FY2020 · HL · contact PI
The myosin light chain regulators of heart function$487,511
R56 · FY2019 · HL · contact PI
Novel cardioskeletal myopathy associated with MYL2$498,844
R01 · FY2018 · HL · contact PI
Novel cardioskeletal myopathy associated with MYL2$498,844
R01 · FY2017 · HL · contact PI
Novel cardioskeletal myopathy associated with MYL2$500,476
R01 · FY2016 · HL · contact PI
Novel cardioskeletal myopathy associated with MYL2$542,614
R01 · FY2015 · HL · contact PI
Myosin ELC, a novel therapeutic target for FHC$379,429
R01 · FY2015 · HL · contact PI
Myosin ELC, a novel therapeutic target for FHC$377,504
R01 · FY2014 · HL · contact PI
Myosin ELC, a novel therapeutic target for FHC$371,280
R01 · FY2013 · HL · contact PI
Myosin ELC, a novel therapeutic target for FHC$406,916
R01 · FY2012 · HL · contact PI
Single Cross-Bridge Kinetics in Transgenic Mouse Hearts Expressing FHC Mutations$396,397
R01 · FY2012 · HL
Functional Consequences of FHC-linked RLC Mutations.$383,943
R01 · FY2012 · HL · contact PI
Single Cross-Bridge Kinetics in Transgenic Mouse Hearts Expressing FHC Mutations$400,400
R01 · FY2011 · HL
Functional Consequences of FHC-linked RLC Mutations.$387,764
R01 · FY2011 · HL · contact PI
Cardiac Troponin in Health and Disease$382,500
R01 · FY2011 · HL · contact PI
Training Program in Cardiovascular Signaling$289,022
T32 · FY2011 · HL · contact PI
THE N-TERMINAL MYOSIN-ELC REGULATION OF CARDIAC MUSCLE CONTRACTION$9,852
P41 · FY2011 · RR · contact PI
Single Cross-Bridge Kinetics in Transgenic Mouse Hearts Expressing FHC Mutations$400,400
R01 · FY2010 · HL
Functional Consequences of FHC-linked RLC Mutations.$387,708
R01 · FY2010 · HL · contact PI
Single Cross-Bridge Kinetics in Transgenic Mouse Hearts Expressing FHC Mutations$411,400
R01 · FY2009 · HL
Functional Consequences of FHC-linked RLC Mutations.$387,654
R01 · FY2009 · HL · contact PI
Functional Consequences of FHC-linked RLC Mutations.$414,102
R01 · FY2008 · HL · contact PI
Functional Consequences of FHC-linked RLC Mutations$369,849
R01 · FY2006 · HL · contact PI
Functional Consequences of FHC-linked RLC Mutations$377,463
R01 · FY2005 · HL
Functional Consequences of FHC-linked RLC Mutations$376,175
R01 · FY2004 · HL
Functional Consequences of FHC-linked RLC Mutations$367,420
R01 · FY2003 · HL